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1. Introduction 
Macular edema (ME) represents a common final pathway of many intraocular and systemic 
diseases, which characterized by the accumulation of extracellular fluid in Henle’s layer and 
the inner nuclear layer of the retina. ME can cause severe visual disturbances and be 
considered to be multifactorial and difficult to treat. It may be most commonly seen following 
diabetic retinopathy, retinal vascular occlusion, intraocular surgery, uveitis, pigmentary 
degeneration, and/or vitreoretinal traction syndrome. The pathogenesis of ME involves the 
interplay of several affected factors, including the breakdown of the inner and outer blood 
retinal barriers, release of biochemical messengers, tissue hypoxia, retinal circulatory changes, 
and vitreous traction. Although medications and some other therapeutic methods are effective 
in some cases, they cannot be the best treatment due to adverse effects or lack of durability. 
Thus, the role of the vitreous in the development of ME has received attention. Abnormal 
glycation cross-linking of vitreal collagen has been found in the vitreous of ME cases. The 
abnormal collagen structure can destabilize the vitreous, leading to traction on the macula [1–7], 
which may distort the BRB and result in ME. On the other hand, the breakdown of the blood 
retinal barriers can lead to a high concentration of vasopermeable and chemoattractant factors 
in the posterior vitreous [8]. This pool of agents can cause cell migration to the posterior 
hyaloid. Contraction of these cells could lead to macular traction with possible development of 
a shallow macular detachment and exacerbation of ME [9,10]. (Fig. 1) Thus, we discuss the 
possibility of surgical treatment for ME in the following.  
2. Vitrectomy 
The role of the vitreous in the formation of DME has been recognized. A few study shows 
that in various disorders, including aphakia, uveitis, branched vein occlusion, and diabetic 
retinopathy, the vitreous could remain attached to the macula with the firm vitreomacular 
adhesions, which could cause traction on the inner limiting membrane (ILM) of the macula 
and exacerbate the ME. When the vitreous was either completely liquefied (Stickler 
syndrome and high myopia) or the hyaloid face had completely detached from the retina, 
the ME could be elimilated [11-12]. This finding demonstrated that the vitreous played a role 
in the development of ME and suggested that complete posterior vitreous detachment had a 
protective effect against the development of ME. Thus, the vitreous could play a role in 
exacerbating the ME, and the treatment of vitrectomy with separation of the posterior 
hyaloid from the macula could be beneficial.  
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Fig. 1. Vitreomacular traction for macular edema. (From Margherio RR, Trese MT, 
Margherio AR et al: Surgical management of vitreomacular traction syndromes. 
Ophthalmology 1989;96:1439) 
Why does vitrectomy and hyaloid removal could relieve ME? The release of vitreomacular 
traction is one obvious mechanism. The tractional force of the posterior hyaloid to the macula 
as seen in vitreomacular traction may be important in the pathogenesis of ME which has been 
well-demonstrated by optical coherence tomography [13]. In addition, vitrectomy appears to 
increase oxygenation of the macula. Kadonoso and colleagues [14] demonstrated increased 
perifoveal capillary blood flow after vitrectomy in their series. Stefansson and associates [15,16] 
reported that vitrectomy with lensectomy allows aqueous to provide increased levels of 
oxygen to the inner retina and that movement of oxygen transcorneally to the vitreous has 
been demonstrated to be more effective in vitrectomized eyes [17]. Therefore, vitrectomy has 
been reported to be beneficial in these situations. Some studies, however, have shown that 
vitrectomy is effective even when there is no evidence of macular traction [18–21]. Perhaps this is 
due to removal of the posterior hyaloid also removes toxic substances, such as histamine, free 
radical scavengers, and VEGF, which may be harbored in the preretinal space [22].  
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Recent advances in vitreous surgery have enabled us to treat surgically eyes with good 
visual acuity. The critical process in vitrectomy is making complete posterior vitreous 
detachment and removing the thickened and attached posterior hyaloids. We have used 
multifocal electroretinogram technique to investigate the effects of vitrectomy on macular 
visual function for diabetic ME, and prospectively evaluated the surgical outcomes in visual 
function. It’s concluded that vitrectomy is helpful not only in reducing ME, and improving 
best correct visual acuity, but also in reinforcing the resume of macular and paramacular 
visual function [23]. (Fig. 2) 
3. Vitrectomy with ILM peel 
Recently, ILM peeling has been added to the procedure of surgical treatment for ME. Addition 
of ILM peel to vitrectomy expedites the resolution of the ME and prevents its recurrence, 
which would appear to enhance the beneficial effects of vitrectomy [24]. The mechanism for this 
was postulated to be the elimination of all tractional forces at the vitreoretinal interface and 
removal of the scaffold used by astrocytes to proliferate on the retinal surface. In additon, it 
was hypothesized that vitrectomy with removal of the ILM would allow the ME to 
decompress by facilitating the release of extracellular fluid into the vitreous, which would, in 
turn, restore normal retinal thickness and intraretinal tissue pressure. Challenges in surgical 
manipulation include poor visibility of the thin transparent membrane and the small 
dimensions and the sensitivity of the macular tissue. More recently, many study demonstrated 
that the technical difficulty of performing ILM peels can be eased with staining that 
specifically targets the ILM [25-29], which including indocyanine green, triamcinolone acetonide, 
trypan blue, whole blood, and brilliant blue G. These were shown selectively to stain the ILM 
and not the posterior vitreous or the underlying retinal layers. The use of indocyanine green in 
ILM removal has been decreased more recently for several reports of indocyanine green 
toxicity. Triamcinolone acetonide, trypan blue and brilliant blue G have become popularly 
used in ILM staining. (Fig. 3) We have treated chronic cystoid ME in branch retinal vein 
occlusion with 25-gauge vitrectomy and TA–assisted ILM peeling, and evaluated the efficacy. 
The result is that TA-assisted ILM peeling is generally effective in reducing ME and improving 
BCVA for CCME in BRVO for at least 7 months [30]. Certainly, the ILM can also be peeled 
without a visualization agent to avoid concerns of toxicity, especially if the ocular media and 
surgeon's view are particularly clear. This would avoid dye toxicity concerns but runs the risk 
of incomplete peeling. But in cases of ME, the adhesion of the ILM to the macula is stronger, 
and the manipulation must be more delicate. Therefore, additional repeated staining may be 
indicated, which decrease the risk of iatrogenic damage from surgical manipulation. 
Nevertheless, the value of ILM removal for treatment of ME has also been questioned recently. 
In a study of 135 eyes, 74 of which underwent ILM peeling, Kumagai and associates [31] found 
that even though ILM removal accelerated the absorption of ME, the final VA and rate of ME 
absorption were similar in both groups. 
4. Vitrectomy with intravitreous pharmacologic therapies 
Recently, intravitreous pharmacologic therapies (including intravitreal TA, VEGF inhibitors 
and protein kinase C beta-isoform inhibitors) have been demonstrated as effective in the 
treatment of ME when other modalities have failed, especially laser, in the setting of retinal 
vascular decompensation ME [32-34]. Intravitreous corticosteroids such as TA have been 
documented to reduce macular leakage in ME retinopathy with or without clinically  
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(A) before vitrectomy, the P1 value of amplitude and latency were 5.8 nv/deg2 and 41.6 msec 
respectively; the best-corrected visual acuity was 0.04. (B) 2 months after vitrectomy, the P1 value of 
amplitude and latency were 6.3 nv/deg2 and 40.2 msec respectively; the best-corrected visual acuity was 
0.08. (C) 4 months after vitrectomy, the P1 value of amplitude and latency were 11.4 nv/deg2  and 32.7 
msec respectively; the best-corrected visual acuity was 0.2. (D) 6 months after vitrectomy, the P1 value 
of amplitude and latency were 16.9 nv/deg2  and 25.3 msec respectively; the best-corrected visual acuity 
was 0.3. Ovals indicate central hexagons (ring1 and ring2 area). (From Ma J et al. Assessment of Macular 
Function by Multifocal Electroretinogram in Diabetic Macular Edema before and after Vitrectomy. 
Documenta Ophthalmologica. 2004;109 (2): 131-137.) 
Fig. 2. The OCT image (left), trace array (Middle) and 3-D topography (right) of multifocal 
ERG for a same case of diabetic macular edema. With the passage of follow up, macular 
edema had decreased and retinal fuction had increased gradually.  
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Fig. 3. Triamcinolone acetonide (TA) assisted internal limiting membrane (ILM)-peeling. The 
ILM is directly grasped with an intraocular forceps and peeled in a circumferential manner 
around the macular edema. The peeled area is clearly observed as lacking the whites specks 
left by the TA. (Supplied by Jin Ma, MD.) 
significant traction from vitreous or preretinal membranes. In this setting, corticosteroids 
appear to be effective by inhibiting both VEGF and macrophage-released factors on the basis 
of mechanisms described here. Corticosteroids may also be important in promoting overall 
endothelial cell repair [35]. VEGF is a peptide growth factor specific for vascular endothelial 
cells and increases vascular permeability and is thought to contribute to capillary wall 
dysfunction [36]. VEGF plays a dominant role in retinal vascular leakage and formation of 
ME. VEGF-A has been implicated as an important factor in the breakdown of the blood–
retina barrier, with increased vascular permeability resulting in retinal edema in diabetes by 
affecting endothelial tight junction proteins [37]. Therefore, VEGF inhibition is another 
promising pharmacologic approach in the management of ME. There are several different 
anti-VEGF drugs which have been used in the management of ME, including pegaptanib 
(Macugen; Eyetech Pharmaceuticals, New York, New York, USA), bevacizumab (Avastin; 
Genentech Inc.), and ranibizumab (Lucentis; Genentech Inc., South San Francisco, 
California). Ruboxistaurin, a selective protein kinase C binhibitor, reduced retinal vascular 
leakage in patients with diabetic ME and reduced the rate of sustained moderate visual loss 
in those with moderately severe to very severe non proliferative diabetic retinopathy [32]. 
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During the surgery, intravitreous pharmaceuticals mentioned above should be drop on the 
surface of fovea, after surgical removal of the posterior hyaloids with or without ILM 
peeling, and an air–fluid exchange carried out. Thus, vitrectomy with intravitreous 
pharmacologic combined therapies could provide clinicians with a set of power tools to treat 
ME, and may lead to a synergistic benefit that is not observed with monotherapy. 
5. Removal of hard exudates and cysts 
Further surgical procedures for ME are being attempted. Longstanding macular deposits 
may cause macular dysfunction and macular atrophy [38]. Direct removal of hard exudates 
was attempted by Takagi et al. [39] in a series of 7 eyes with massive hard exudates. They 
performed removal of the exudates by aspiration with a silicone-tipped extrusion needle or 
by direct removal with intraocular forceps. The final postoperative visual acuity was bad. In 
addition, intraoperative iatrogenic macular holes can be caused by the removal of neural 
retina surrounding the removed exudates. This complication rate mandates caution in using 
this technique. 
Tachi et al. [40] attempted treatment of diabetic cystoid ME with cystotomy or cystectomy in 
addition to vitrectomy with posterior hyaloid removal. Despite resolution of cystoid ME in a 
few cases, there were several reported complications, including intraoperative retinal tears, 
and cyst reformation. The study could not demonstrate that this technique was superior to 
vitrectomy and posterior hyaloid removal alone. 
6. Conclusions 
Even so, laser photocoagulation remains the treatment of choice for ME associated with 
nondiffuse patterns of vascular leakage [41]. The action of photocoagulation is not fully 
known, but it is suspected that the method of treatment as described here not only 
cauterizes focally leaking sites, but also leads to vasoconstriction, the latter possibly by 
decreasing oxygen consumption in the outer retinal layers and increasing oxygen tension in 
the inner retinal layers [42]. Vitreous surgery is often effective in resolving ME associated 
with vitreoretinal or epiretinal traction and yields variable results in nontractional cases. A 
variety of pharmacologic agents targeting inflammatory and vasopermeability molecules 
have been shown to reduce diffuse ME and improve visual function over the short-term. 
Although treatment options continue to expand with the development of new drugs and 
surgical procedures, the long-term efficacy and safety of most new approaches have yet to 
be established in randomized, controlled clinical trials. We should be clear that this is a 
complicated disease which has been far than thoroughly investigated, which needs our 
further research on its pathogenesis thus leading to the introduction of additional 
pharmacological agents for the treatment and reduction of visual loss of ME. A variety of 
promising new medical and surgical therapies are under investigation, but additional 
clinical research is required to determine their role alone or in combination.  
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